NFE2L2/NRF2 Activity Is Linked to Mitochondria and AMP-Activated Protein Kinase Signaling in Cancers Through MIR-181c/Mitochondria-Encoded Cytochrome c Oxidase Regulation

Antioxidants and Redox Signaling

Volumn 27, Issue 13, 2017, Pages 945-961

  Jung, Kyeong Ah ^a   Lee, Sujin ^a   Kwak, Mi Kyoung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

AMP activated protein kinase; Electron transport chain; MIR 181c; Mitochondria encoded cytochrome c oxidase subunit 1; NFE2L2 NRF2

Indexed keywords

ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE ALPHA; ADENOSINE TRIPHOSPHATE; CYTOCHROME C OXIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 124 2 3P; MICRORNA 146A 5P; MICRORNA 181C; MICRORNA 181C 5P; MICRORNA 1908 5P; MICRORNA 200A 3P; MICRORNA 2278 5P; MICRORNA 2392 5P; MICRORNA 3122 5P; MICRORNA 3152 3P; MICRORNA 3188 5P; MICRORNA 3201 5P; MICRORNA 3921 5P; MICRORNA 3960 5P; MICRORNA 4466 5P; MICRORNA 4490 5P; MICRORNA 4532 5P; MICRORNA 4720 5P; MICRORNA 4763 3P; MICRORNA 4787 5P; MICRORNA 548Q 5P; MICRORNA 93 3P; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; CYTOCHROME C OXIDASE SUBUNIT I, HUMAN; MIRN181 MICRORNA, HUMAN; NFE2L2 PROTEIN, HUMAN;

AMPK SIGNALING; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL COUNT; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SYNTHESIS; GLUCOSE UTILIZATION; HUMAN; HUMAN CELL; MALIGNANT NEOPLASM; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RESPIRATORY CHAIN; RNA ISOLATION; SIGNAL TRANSDUCTION; STEROL SYNTHESIS; TRANSCRIPTION INITIATION; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; COLON TUMOR; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; METABOLISM;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; COLONIC NEOPLASMS; ELECTRON TRANSPORT COMPLEX IV; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; MICE; MICRORNAS; MITOCHONDRIA; NEOPLASM TRANSPLANTATION; NF-E2-RELATED FACTOR 2; SIGNAL TRANSDUCTION;

EID: 85030232861     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2016.6797     Document Type: Article

References (59)

1. Arnold S. The power of life-cytochrome c oxidase takes center stage in metabolic control, cell signalling and survival. Mitochondrion 12: 46-56, 2012.
2. Aschrafi A, Schwechter AD, Mameza MG, Natera-Naranjo O, Gioio AE, and Kaplan BB. MicroRNA-338 regulates local cytochrome c oxidase IV mRNA levels and oxidative phosphorylation in the axons of sympathetic neurons. J Neurosci 28: 12581-12590, 2008.
3. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, and Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315, 2007.
4. Bandiera S, Mategot R, Girard M, Demongeot J, and Henrion-Caude A. MitomiRs delineating the intracellular localization of microRNAs at mitochondria. Free Radic Biol Med 64: 12-19, 2013.
5. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, Wang T, Chen WW, Clish CB, and Sabatini DM. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 508: 108-112, 2014.
6. Bungard D, Fuerth BJ, Zeng PY, Faubert B, Maas NL, Viollet B, Carling D, Thompson CB, Jones RG, and Berger SL. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science 329: 1201-1205, 2010.
7. Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, and Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab 10: 273-284, 2009.
8. Chartoumpekis DV and Kensler TW. New player on an old field; the keap1/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome. Curr Diabetes Rev 9: 137-145, 2013.
9. Choi BH, Ryoo IG, Kang HC, and Kwak MK. The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing. PLoS One 9: e107158, 2014.
10. Das S, Bedja D, Campbell N, Dunkerly B, Chenna V, Maitra A, and Steenbergen C. miR-181c regulates the mitochondrial genome, bioenergetics, and propensity for heart failure in vivo. PLoS One 9: e96820, 2014.
11. Das S, Ferlito M, Kent OA, Fox-Talbot K, Wang R, Liu D, Raghavachari N, Yang Y, Wheelan SJ, Murphy E, and Steenbergen C. Nuclear miRNA regulates the mitochondrial genome in the heart. Circ Res 110: 1596-1603, 2012.
12. DiMauro S and Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 348: 2656-2668, 2003.
13. Dinkova-Kostova AT and Abramov AY. The emerging role of Nrf2 in mitochondrial function. Free Radic Biol Med 88: 179-188, 2015.
14. Dong DW, Srinivasan S, Guha M, and Avadhani NG. Defects in cytochrome c oxidase expression induce a metabolic shift to glycolysis and carcinogenesis. Genom Data 6: 99-107, 2015.
15. Furukawa R, Yamada Y, Kawamura E, and Harashima H. Mitochondrial delivery of antisense RNA by MITO-Porter results in mitochondrial RNA knockdown, and has a functional impact on mitochondria. Biomaterials 57: 107-115, 2015.
16. Gao SP, Sun HF, Jiang HL, Li LD, Hu X, Xu XE, and Jin W. Loss of COX5B inhibits proliferation and promotes senescence via mitochondrial dysfunction in breast cancer. Oncotarget 6: 43363-43374, 2015.
17. Hagen T, Taylor CT, Lam F, and Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 302: 1975-1978, 2003.
18. Handy DE and Loscalzo J. Redox regulation of mitochondrial function. Antioxid Redox Signal 16: 1323-1367, 2012.
19. Hayes JD and McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34: 176-188, 2009.
20. Holmstrom KM, Baird L, Zhang Y, Hargreaves I, Chalasani A, Land JM, Stanyer L, Yamamoto M, Dinkova-Kostova AT, and Abramov AY. Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration. Biol Open 2: 761-770, 2013.
21. Hutchison ER, Kawamoto EM, Taub DD, Lal A, Abdelmohsen K, Zhang Y, Wood WH, 3rd, Lehrmann E, Camandola S, Becker KG, Gorospe M, and Mattson MP. Evidence for miR-181 involvement in neuroinflammatory responses of astrocytes. Glia 61: 1018-1028, 2013.
22. Inoki K, Zhu T, and Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590, 2003.
23. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, and Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236: 313-322, 1997.
24. Itoh K,WakabayashiN,Katoh Y, IshiiT, IgarashiK,Engel JD, and Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13: 76-86, 1999.
25. Itoh K, Ye P, Matsumiya T, Tanji K, and Ozaki T. Emerging functional cross-talk between the Keap1-Nrf2 system and mitochondria. J Clin Biochem Nutr 56: 91-97, 2015.
26. Joo MS, Kim WD, Lee KY, Kim JH, Koo JH, and Kim SG. AMPK facilitates nuclear accumulation of Nrf2 by phosphorylating at serine 550. Mol Cell Biol 36: 1931-1942, 2016.
27. Jung KA, Choi BH, and Kwak MK. The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression. Mol Pharmacol 87: 465-476, 2015.
28. Jung KA, Choi BH, Nam CW, Song M, Kim ST, Lee JY, and Kwak MK. Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Toxicol Lett 218: 39-49, 2013.
29. Kadenbach B and Huttemann M. The subunit composition and function of mammalian cytochrome c oxidase. Mitochondrion 24: 64-76, 2015.
30. Kahn BB, Alquier T, Carling D, and Hardie DG. AMPactivated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25, 2005.
31. Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D, Lee YM, Ku SK, Jung Y, and Kwak MK. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Cancer Res 71: 2260-2275, 2011.
32. Kren BT,Wong PY, Sarver A, ZhangX, Zeng Y, and Steer CJ. MicroRNAs identified in highly purified liver-derived mitochondriamay play a role in apoptosis.RNABiol 6: 65-72, 2009.
33. Liang J and Mills GB. AMPK: a contextual oncogene or tumor suppressor? Cancer Res 73: 2929-2935, 2013.
34. Liu G, Min H, Yue S, and Chen CZ. Pre-miRNA loop nucleotides control the distinct activities of mir-181a-1 and mir-181c in early T cell development. PLoS One 3: e3592, 2008.
35. Liu X, Chhipa RR, Nakano I, and Dasgupta B. The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent. Mol Cancer Ther 13: 596-605, 2014.
36. Liu XM, Peyton KJ, Shebib AR, Wang H, Korthuis RJ, and Durante W. Activation of AMPK stimulates heme oxygenase-1 gene expression and human endothelial cell survival. Am J Physiol Heart Circ Physiol 300: H84-H93, 2011.
37. Ludtmann MH, Angelova PR, Zhang Y, Abramov AY, and Dinkova-Kostova AT. Nrf2 affects the efficiency of mitochondrial fatty acid oxidation. Biochem J 457: 415-424, 2014.
38. Mateo J, Garcia-Lecea M, Cadenas S, Hernandez C, and Moncada S. Regulation of hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and-independent pathways. Biochem J 376: 537-544, 2003.
39. Mihaylova MM and Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13: 1016-1023, 2011.
40. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, and Motohashi H. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22: 66-79, 2012.
41. Moran M, Moreno-Lastres D, Marin-Buera L, Arenas J, Martin MA, and Ugalde C. Mitochondrial respiratory chain dysfunction: implications in neurodegeneration. Free Radic Biol Med 53: 595-609, 2012.
42. Nunnari J and Suomalainen A. Mitochondria: in sickness and in health. Cell 148: 1145-1159, 2012.
43. O'Connell MA and Hayes JD. The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic. Biochem Soc Trans 43: 687-689, 2015.
44. Owen MR, Doran E, and Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348 Pt 3: 607-614, 2000.
45. Ryoo IG, Choi BH, and Kwak MK. Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells. Oncotarget 6: 8167-8184, 2015.
46. Ryoo IG, Shin DH, Kang KS, and Kwak MK. Involvement of Nrf2-GSH signaling in TGFbeta1-stimulated epithelial-tomesenchymal transition changes in rat renal tubular cells. Arch Pharm Res 38: 272-281, 2015.
47. Shackelford DB and Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9: 563-575, 2009.
48. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M, and Hirohashi S. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A 105: 13568-13573, 2008.
49. Singh A, Happel C, Manna SK, Acquaah-Mensah G, Carrerero J, Kumar S, Nasipuri P, Krausz KW, Wakabayashi N, Dewi R, Boros LG, Gonzalez FJ, Gabrielson E, Wong KK, Girnun G, and Biswal S. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest 123: 2921-2934, 2013.
50. Slater EC. Mechanism of oxidative phosphorylation. Annu Rev Biochem 46: 1015-1026, 1977.
51. Sun F, Zhou Q, Pang X, Xu Y, and Rao Z. Revealing various coupling of electron transfer and proton pumping in mitochondrial respiratory chain. Curr Opin Struct Biol 23: 526-538, 2013.
52. Suzuki T, Motohashi H, and Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci 34: 340-346, 2013.
53. Suzuki T and Yamamoto M. Molecular basis of the Keap1-Nrf2 system. Free Radic Biol Med 88: 93-100, 2015.
54. Taguchi K, Motohashi H, and Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16: 123-140, 2011.
55. Takahashi N, Nakaoka T, and Yamashita N. Profiling of immune-related microRNA expression in human cord blood and adult peripheral blood cells upon proinflammatory stimulation. Eur J Haematol 88: 31-38, 2012.
56. Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT, and Hayes JD. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic Biol Med 88: 108-146, 2015.
57. Villeneuve NF, Lau A, and Zhang DD. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxid Redox Signal 13: 1699-1712, 2010.
58. Xiao B, Sanders MJ, Underwood E, Heath R, Mayer FV, Carmena D, Jing C, Walker PA, Eccleston JF, Haire LF, Saiu P, Howell SA, Aasland R, Martin SR, Carling D, and Gamblin SJ. Structure of mammalian AMPK and its regulation by ADP. Nature 472: 230-233, 2011.
59. Zadra G, Batista JL, and Loda M. Dissecting the dual role of AMPK in cancer: from experimental to human studies. Mol Cancer Res 13: 1059-1072, 2015.